{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:16:49Z","timestamp":1783383409626,"version":"3.54.6"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-51933-w","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:43:31Z","timestamp":1778082211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Muscle loss and pentraxin-3 as predictors of immunotherapy outcomes in non-small cell lung cancer: a prospective study"],"prefix":"10.1038","volume":"16","author":[{"given":"Takaaki","family":"Masuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Shono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Yanagimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Saida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumasa","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Koya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiko","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"51933_CR1","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl. J. Med. 372, 2018\u20132028. https:\/\/doi.org\/10.1056\/NEJMoa1501824 (2015).","journal-title":"N Engl. J. Med."},{"key":"51933_CR2","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl. J. Med. 378, 2288\u20132301. https:\/\/doi.org\/10.1056\/NEJMoa1716948 (2018).","journal-title":"N Engl. J. Med."},{"key":"51933_CR3","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann, M. D. et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl. J. Med. 381, 2020\u20132031. https:\/\/doi.org\/10.1056\/NEJMoa1910231 (2019).","journal-title":"N Engl. J. Med."},{"key":"51933_CR4","doi-asserted-by":"publisher","first-page":"100463","DOI":"10.1016\/j.esmoop.2022.100463","volume":"7","author":"E Grande","year":"2022","unstructured":"Grande, E. et al. Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy. ESMO Open. 7, 100463. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100463 (2022).","journal-title":"ESMO Open."},{"key":"51933_CR5","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","volume":"35","author":"NM Tannir","year":"2024","unstructured":"Tannir, N. M. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann. Oncol. 35, 1026\u20131038. https:\/\/doi.org\/10.1016\/j.annonc.2024.07.727 (2024).","journal-title":"Ann. Oncol."},{"key":"51933_CR6","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck, M. et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >\/= 50. J. Clin. Oncol. 39, 2339\u20132349. https:\/\/doi.org\/10.1200\/JCO.21.00174 (2021).","journal-title":"J. Clin. Oncol."},{"key":"51933_CR7","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.22.01503","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer, J. R. et al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. J. Clin. Oncol. 41, 1200\u20131212. https:\/\/doi.org\/10.1200\/JCO.22.01503 (2023).","journal-title":"J. Clin. Oncol."},{"key":"51933_CR8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis, A. A. & Patel, V. G. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J. Immunother Cancer. 7, 278. https:\/\/doi.org\/10.1186\/s40425-019-0768-9 (2019).","journal-title":"J. Immunother Cancer"},{"key":"51933_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206. https:\/\/doi.org\/10.1038\/s41588-018-0312-8 (2019).","journal-title":"Nat. Genet."},{"key":"51933_CR10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ageing\/afq034","volume":"39","author":"AJ Cruz-Jentoft","year":"2010","unstructured":"Cruz-Jentoft, A. J. et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 39, 412\u2013423. https:\/\/doi.org\/10.1093\/ageing\/afq034 (2010).","journal-title":"Age Ageing"},{"key":"51933_CR11","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1097\/JS9.0000000000000688","volume":"109","author":"S Knoedler","year":"2023","unstructured":"Knoedler, S. et al. Impact of sarcopenia on outcomes in surgical patients: a systematic review and meta-analysis. Int. J. Surg. 109, 4238\u20134262. https:\/\/doi.org\/10.1097\/JS9.0000000000000688 (2023).","journal-title":"Int. J. Surg."},{"key":"51933_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.radonc.2020.03.014","volume":"147","author":"MI van Rijn-Dekker","year":"2020","unstructured":"van Rijn-Dekker, M. I. et al. Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapy. Radiother Oncol. 147, 103\u2013110. https:\/\/doi.org\/10.1016\/j.radonc.2020.03.014 (2020).","journal-title":"Radiother Oncol."},{"key":"51933_CR13","doi-asserted-by":"publisher","first-page":"1113875","DOI":"10.3389\/fnut.2023.1113875","volume":"10","author":"J Lyu","year":"2023","unstructured":"Lyu, J. et al. Prognostic value of sarcopenia in patients with lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors. Front. Nutr. 10, 1113875. https:\/\/doi.org\/10.3389\/fnut.2023.1113875 (2023).","journal-title":"Front. Nutr."},{"key":"51933_CR14","doi-asserted-by":"publisher","first-page":"986236","DOI":"10.3389\/fonc.2022.986236","volume":"12","author":"FJ Bolte","year":"2022","unstructured":"Bolte, F. J. et al. Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy. Front. Oncol. 12, 986236. https:\/\/doi.org\/10.3389\/fonc.2022.986236 (2022).","journal-title":"Front. Oncol."},{"key":"51933_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10120-020-01124-x","volume":"24","author":"YY Kim","year":"2021","unstructured":"Kim, Y. Y. et al. Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. Gastric Cancer. 24, 457\u2013466. https:\/\/doi.org\/10.1007\/s10120-020-01124-x (2021).","journal-title":"Gastric Cancer"},{"key":"51933_CR16","doi-asserted-by":"publisher","first-page":"900823","DOI":"10.3389\/fnut.2022.900823","volume":"9","author":"S Li","year":"2022","unstructured":"Li, S. et al. Sarcopenia Was a Poor Prognostic Predictor for Patients With Advanced Lung Cancer Treated With Immune Checkpoint Inhibitors. Front. Nutr. 9, 900823. https:\/\/doi.org\/10.3389\/fnut.2022.900823 (2022).","journal-title":"Front. Nutr."},{"key":"51933_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000520833","volume":"100","author":"T Herrmann","year":"2022","unstructured":"Herrmann, T. et al. Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma. Oncology 100, 114\u2013123. https:\/\/doi.org\/10.1159\/000520833 (2022).","journal-title":"Oncology"},{"key":"51933_CR18","doi-asserted-by":"publisher","unstructured":"Shimizu, T. et al. Clinical Impact of Sarcopenia and Inflammatory\/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab. Diagnostics (Basel). 10 https:\/\/doi.org\/10.3390\/diagnostics10050310 (2020).","DOI":"10.3390\/diagnostics10050310"},{"key":"51933_CR19","doi-asserted-by":"publisher","unstructured":"Lee, S. Y. et al. Comparison between Dual-Energy X-ray Absorptiometry and Bioelectrical Impedance Analyses for Accuracy in Measuring Whole Body Muscle Mass and Appendicular Skeletal Muscle Mass. Nutrients 10. https:\/\/doi.org\/10.3390\/nu10060738 (2018)","DOI":"10.3390\/nu10060738"},{"key":"51933_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jamda.2013.11.025","volume":"15","author":"LK Chen","year":"2014","unstructured":"Chen, L. K. et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J. Am. Med. Dir. Assoc. 15, 95\u2013101. https:\/\/doi.org\/10.1016\/j.jamda.2013.11.025 (2014).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"51933_CR21","doi-asserted-by":"publisher","unstructured":"Armstrong, V. S., Fitzgerald, L. W. & Bathe, O. F. Cancer-Associated Muscle Wasting-Candidate Mechanisms and Molecular Pathways. Int. J. Mol. Sci. 21 https:\/\/doi.org\/10.3390\/ijms21239268 (2020).","DOI":"10.3390\/ijms21239268"},{"key":"51933_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12919","author":"X Meng","year":"2022","unstructured":"Meng, X. et al. Cathepsin K activity controls cachexia-induced muscle atrophy via the modulation of IRS1 ubiquitination. J. Cachexia Sarcopenia Muscle. https:\/\/doi.org\/10.1002\/jcsm.12919 (2022).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"51933_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bone.2015.03.015","volume":"80","author":"P Londhe","year":"2015","unstructured":"Londhe, P. & Guttridge, D. C. Inflammation induced loss of skeletal muscle. Bone 80, 131\u2013142. https:\/\/doi.org\/10.1016\/j.bone.2015.03.015 (2015).","journal-title":"Bone"},{"key":"51933_CR24","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.arr.2016.09.008","volume":"35","author":"A Kalinkovich","year":"2017","unstructured":"Kalinkovich, A. & Livshits, G. Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res. Rev. 35, 200\u2013221. https:\/\/doi.org\/10.1016\/j.arr.2016.09.008 (2017).","journal-title":"Ageing Res. Rev."},{"key":"51933_CR25","doi-asserted-by":"publisher","unstructured":"Romanello, V. The Interplay between Mitochondrial Morphology and Myomitokines in Aging Sarcopenia. Int. J. Mol. Sci. 22 https:\/\/doi.org\/10.3390\/ijms22010091 (2020).","DOI":"10.3390\/ijms22010091"},{"key":"51933_CR26","doi-asserted-by":"publisher","first-page":"101200","DOI":"10.1016\/j.arr.2020.101200","volume":"65","author":"P Wiedmer","year":"2021","unstructured":"Wiedmer, P. et al. Sarcopenia - Molecular mechanisms and open questions. Ageing Res. Rev. 65, 101200. https:\/\/doi.org\/10.1016\/j.arr.2020.101200 (2021).","journal-title":"Ageing Res. Rev."},{"key":"51933_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jnutbio.2009.06.014","volume":"21","author":"JS Kim","year":"2010","unstructured":"Kim, J. S., Wilson, J. M. & Lee, S. R. Dietary implications on mechanisms of sarcopenia: roles of protein, amino acids and antioxidants. J. Nutr. Biochem. 21, 1\u201313. https:\/\/doi.org\/10.1016\/j.jnutbio.2009.06.014 (2010).","journal-title":"J. Nutr. Biochem."},{"key":"51933_CR28","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/jcsm.13073","volume":"14","author":"A Martin","year":"2023","unstructured":"Martin, A., Gallot, Y. S. & Freyssenet, D. Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies. J. Cachexia Sarcopenia Muscle. 14, 1150\u20131167. https:\/\/doi.org\/10.1002\/jcsm.13073 (2023).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"51933_CR29","doi-asserted-by":"publisher","first-page":"582258","DOI":"10.3389\/fphys.2020.582258","volume":"11","author":"PS Rogeri","year":"2020","unstructured":"Rogeri, P. S. et al. Crosstalk Between Skeletal Muscle and Immune System: Which Roles Do IL-6 and Glutamine Play? Front. Physiol. 11, 582258. https:\/\/doi.org\/10.3389\/fphys.2020.582258 (2020).","journal-title":"Front. Physiol."},{"key":"51933_CR30","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.autrev.2017.12.005","volume":"17","author":"AM Afzali","year":"2018","unstructured":"Afzali, A. M., Muntefering, T., Wiendl, H., Meuth, S. G. & Ruck, T. Skeletal muscle cells actively shape (auto)immune responses. Autoimmun. Rev. 17, 518\u2013529. https:\/\/doi.org\/10.1016\/j.autrev.2017.12.005 (2018).","journal-title":"Autoimmun. Rev."},{"key":"51933_CR31","doi-asserted-by":"publisher","first-page":"1133355","DOI":"10.3389\/fimmu.2023.1133355","volume":"14","author":"H Tu","year":"2023","unstructured":"Tu, H. & Li, Y. L. Inflammation balance in skeletal muscle damage and repair. Front. Immunol. 14, 1133355. https:\/\/doi.org\/10.3389\/fimmu.2023.1133355 (2023).","journal-title":"Front. Immunol."},{"key":"51933_CR32","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1152\/physrev.00016.2017","volume":"98","author":"C Garlanda","year":"2018","unstructured":"Garlanda, C., Bottazzi, B., Magrini, E., Inforzato, A. & Mantovani, A. PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and Cancer. Physiol. Rev. 98, 623\u2013639. https:\/\/doi.org\/10.1152\/physrev.00016.2017 (2018).","journal-title":"Physiol. Rev."},{"key":"51933_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/imr.12476","volume":"274","author":"K Daigo","year":"2016","unstructured":"Daigo, K. et al. Pentraxins in the activation and regulation of innate immunity. Immunol. Rev. 274, 202\u2013217. https:\/\/doi.org\/10.1111\/imr.12476 (2016).","journal-title":"Immunol. Rev."},{"key":"51933_CR34","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3389\/fimmu.2019.00794","volume":"10","author":"R Porte","year":"2019","unstructured":"Porte, R. et al. The Long Pentraxin PTX3 as a Humoral Innate Immunity Functional Player and Biomarker of Infections and Sepsis. Front. Immunol. 10, 794. https:\/\/doi.org\/10.3389\/fimmu.2019.00794 (2019).","journal-title":"Front. Immunol."},{"key":"51933_CR35","doi-asserted-by":"publisher","first-page":"112480","DOI":"10.1016\/j.exger.2024.112480","volume":"193","author":"Y He","year":"2024","unstructured":"He, Y. et al. Exploring the impact of interleukins on sarcopenia development: A systematic review and meta-analysis. Exp. Gerontol. 193, 112480. https:\/\/doi.org\/10.1016\/j.exger.2024.112480 (2024).","journal-title":"Exp. Gerontol."},{"key":"51933_CR36","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1111\/cas.15569","volume":"113","author":"K Sato","year":"2022","unstructured":"Sato, K. et al. Pentraxin 3 is an adipose tissue-related serum marker for pancreatic cancer cachexia predicting subsequent muscle mass and visceral fat loss. Cancer Sci. 113, 4311\u20134326. https:\/\/doi.org\/10.1111\/cas.15569 (2022).","journal-title":"Cancer Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51933-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51933-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51933-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:58:38Z","timestamp":1783382318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51933-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51933"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51933-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Watanabe reports grants from Boehringer Ingelheim and Nippon Kayaku, and speaking fees from Lilly, Chugai Pharma, Ono Pharmaceutical, Taiho Pharmaceutical, Kyowa Kirin, Takeda Pharmaceutical, AstraZeneca, Novartis Pharma, Bristol-Myers, Daiichi Sankyo, Nippon Kayaku, Merck, and Celltrion outside of the submitted work. Dr. Yanagimura reports speaking fees from MSD outside the submitted work. Dr. Nozaki reports speaking fees from AstraZeneca, Bristol-Myers, MSD, Taiho Pharmaceutical, Ono Pharmaceutical, and Chugai Pharma outside the submitted work. Dr. Tanaka reports speaking fees from Chugai Pharma and Takeda Pharmaceutical outside the submitted work. Dr. Saida reports Chugai Pharma, Lilly, Astra Zeneca and Ono Pharmaceutical outside the submitted work. Dr. Kikuchi reports grants from Nobel Pharma, Taiho Pharmaceutical, Shionogi, Asahi Kasei, Nippon Kayaku, Boehringer Ingelheim, KYORIN Pharmaceutical, Chugai Pharma, Daiichi Sankyo, and TEIJIN PHARMA outside the submitted work. He also reports consulting fees from AN2 Therapeutics, and speaking fees from Viatris, Insmed, Terumo, AstraZeneca, KYORIN Pharmaceutical, Bristol-Myers, Eisai, Chugai Pharma, Sumitomo Pharma, MSD, Shionogi, Taiho Pharmaceutical, Astellas Pharma, Boehringer Ingelheim, Eli Lilly, and Daiichi Sankyo. Novartis, Merck, NIPRO, Ono Pharmaceutical, GSK, Kyowa Kirin, Sanofi, and Meiji Seika Pharma outside the submitted work. Additionally, he reported participating on the advisory board outside of the submitted work. Dr. Ishikawa reports speaking fees from Eisai and Chugai Pharmaceutical outside the submitted work. Dr. Sakai reports speaking fees from Qiagen, Nippon Kayaku and Takeda Pharmaceutica outside the submitted work. Dr. Nishio reports speaking fees from Chugai, MSD, Ono and AstraZeneca outside the submitted work. No disclosures were reported by the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (revised in 2013) and approved by the Ethics Committee of Niigata University (registration number: 2019-0233). All patients who participated in this study provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"20915"}}